Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs
Authors:
Open Access
- 1 September 1979
- journal article
- case report
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 55 (647) , 657-661
Abstract
Summary: Miconazole, a parenterally administered imidazole antifungal agent has been shown to produce responses in systemic fungal infections in man. Ketoconazole, an analogue, can be given by mouth. It is inhibitory in vitro at low concentrations to most fungi. Blood levels after oral administration to animals and man greatly exceed these inhibitory concentrations for several hours. The efficacy of this drug has been demonstrated in animal models. Initial clinical evaluation has produced responses to therapy with 200–400 mg/day in 13 of 16 evaluable patients with systemic and superficial fungal infections, involving 10 fungal pathogens. No toxicity has been noted to date in these human studies. Ketoconazole is a promising agent needing further extensive evaluation.Keywords
This publication has 13 references indexed in Scilit:
- MOUSE MODEL OF PULMONARY BLASTOMYCOSIS - UTILITY, SIMPLICITY, AND QUANTITATIVE PARAMETERS1978
- Miconazole in the treatment of chronic mucocutaneous candidiasis: A preliminary reportThe Journal of Pediatrics, 1977
- Miconazole treatment in candidal oesophagitis.1977
- MICONAZOLE IN TREATMENT OF SYSTEMIC FUNGAL INFECTIONS1977
- Miconazole in oral candidiasis.1977
- R34000, Á Dioxolane Imidazole in the Therapy for Experimental CoccidioidomycosisChest, 1976
- Antimicrobial Susceptibility Testing of Yeasts: a Turbidimetric Technique Independent of Inoculum SizeAntimicrobial Agents and Chemotherapy, 1976
- Miconazole in Coccidioidomycosis. I. Assays of Activity in Mice and in VitroThe Journal of Infectious Diseases, 1975
- MiconazoleDrugs, 1975
- Miconazole, a Broad-Spectrum Antimycotic Agent with Antibacterial ActivityChemotherapy, 1972